Haptoglobin (Hp) is an alpha-2 glycoprotein primarily synthesized by the liver. Its main physiological function is to bind irreversibly to free hemoglobin (Hb) released from red blood cells (RBCs) during intravascular hemolysis [1, 2]. This binding forms a haptoglobin-hemoglobin complex, which is then rapidly cleared from circulation by macrophages via the CD163 receptor [3]. This mechanism is crucial for preventing hemoglobin-mediated oxidative damage to tissues, conserving iron, and exhibiting indirect antibacterial activity by reducing iron availability for bacteria [3].

Clinical Significance for Pharmacists: Understanding haptoglobin’s role is vital for clinical pharmacists as it serves as a sensitive biomarker for hemolytic conditions and can be influenced by various medications and disease states. Its levels can guide diagnostic pathways, monitor disease progression, and inform therapeutic decisions, particularly in patients with anemia, inflammatory conditions, or those undergoing blood transfusions [1, 2].

2. Laboratory Interpretation

2.1. Normal Ranges

The normal reference range for haptoglobin is typically 41 to 165 milligrams per deciliter (mg/dL) or 410 to 1,650 milligrams per liter (mg/L). It is important to note that normal values may vary slightly between different laboratories due to variations in measurement methods or samples [1].

2.2. Causes of Low Haptoglobin

• Low haptoglobin levels are primarily indicative of increased destruction of red blood cells, as haptoglobin is consumed more rapidly than it can be produced by the liver. Common causes include [1, 2]:
• Hemolytic Anemia: This is the most frequent reason for decreased haptoglobin, where RBCs are destroyed faster than they can be replaced.
• Liver Disease: Chronic liver disease can impair haptoglobin synthesis, leading to lower levels.
• Transfusion Reactions: Adverse reactions to blood transfusions can cause acute hemolysis and a subsequent drop in haptoglobin.
• Hematoma: Blood accumulation under the skin can also lead to localized hemoglobin release and haptoglobin consumption.
• Infants under six months: Physiologically lower haptoglobin levels are normal in this age group [2].

2.3. Causes of High Haptoglobin

As an acute-phase reactant, haptoglobin levels can be elevated in various inflammatory and infectious conditions [1, 2, 3]:

• Inflammatory Conditions: Joint or muscle inflammation, ulcerative colitis, and other systemic inflammatory diseases.
• Infections: Severe infections can trigger an acute-phase response.
• Bile Duct Blockage: Obstruction of bile ducts.
• Peptic Ulcer: Gastric or duodenal ulcers.
• Diabetes: Elevated levels have been observed in patients with diabetes [2].
• Trauma and Burns: These can also lead to elevated haptoglobin as part of the acute-phase response [3].

2.4. Factors Affecting Results

• Several factors can influence haptoglobin levels, which pharmacists should consider when interpreting results [1, 2]:
• Medications: Certain drugs can directly impact haptoglobin levels (see Section 3.1).
• Kidney Function: Severe blood loss and conditions that worsen kidney function may affect haptoglobin levels [2].
• Genetic Polymorphisms: Human haptoglobin has three main subtypes (Hp 1-1, Hp 1-2, Hp 2-2) which can influence its functional properties and potentially its measured levels, though this is more relevant in research settings [3].

3. Drug Interactions and Therapeutic Considerations

3.1. Medications Affecting Haptoglobin Levels

Clinical pharmacists should be aware of medications that can alter haptoglobin levels, potentially confounding diagnostic interpretations or indicating drug-induced effects [1, 2]:

Medications that may raise haptoglobin levels:

• Androgens
• Corticosteroids

Medications that may lower haptoglobin levels:

• Birth control pills
• Chlorpromazine
• Diphenhydramine
• Indomethacin
• Isoniazid
• Nitrofurantoin
• Quinidine
• Streptomycin

It is crucial to consider a patient’s medication regimen when evaluating haptoglobin results and to communicate any potential drug-induced alterations to the healthcare team.

3.2. Therapeutic Implications and Future Directions

• Haptoglobin’s role in binding free hemoglobin makes it a potential therapeutic agent, particularly in conditions involving significant intravascular hemolysis and associated oxidative stress [3, 4].
• Hemolytic Anemias: Haptoglobin administration has been explored to prevent or treat adverse events associated with hemolysis, such as kidney injury in cases of high plasma hemoglobin concentrations [4, 5].
• Oxidative Stress and Inflammation: Haptoglobin possesses antioxidant and anti-inflammatory properties. Recombinant haptoglobin has shown promise in mitigating oxidative damage by sequestering free hemoglobin [3].
• Drug Development: The ability of haptoglobin to compartmentalize cell-free hemoglobin offers opportunities for drug development in diseases like sickle cell anemia and sepsis [4].
• Pharmacists may encounter haptoglobin as a diagnostic marker or, in the future, as a therapeutic intervention. Awareness of its mechanisms and clinical applications will be increasingly important.

4. Conclusion

Haptoglobin is a critical protein in the body’s defense against free hemoglobin toxicity, serving as a valuable biomarker for hemolytic conditions and inflammatory states. Clinical pharmacists play a key role in interpreting haptoglobin levels, considering potential drug interactions, and understanding its evolving therapeutic applications. A thorough understanding of haptoglobin’s physiology and clinical context enables pharmacists to contribute significantly to patient care, optimizing diagnostic accuracy and therapeutic outcomes.

5. References

[1] UCSF Health. Haptoglobin blood test. Available at: https://www.ucsfhealth.org/medical-tests/haptoglobin-blood-test

[2] MedlinePlus. Haptoglobin (HP) Test. Available at: https://medlineplus.gov/lab-tests/haptoglobin-hp-test/

[3] ScienceDirect. Haptoglobin – an overview. Available at: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/haptoglobin

[4] Buehler, P. W. (2020). Haptoglobin Therapeutics and Compartmentalization of Cell-Free Hemoglobin. Trends in Molecular Medicine, 26(8), 731-742. Available at: https://pubmed.ncbi.nlm.nih.gov/32589936/